Aligos Therapeutics, Inc.

ALGS

US01626L1052

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-10 EDT			5-day change	1st Jan Change
0.7303 ^USD	-5.95%		-9.85%	+9.98%

04-03	Aligos Therapeutics, Inc. Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects	CI
03-27	Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies	CI

Aligos Therapeutics, Inc. announced that it has received $92.149997 million in funding from EcoR1 Capital, LLC, Deep Track Capital, LP, Armistice Capital LLC, Roche Venture Fund

October 24, 2023

On October 25, 2023, Aligos Therapeutics, Inc. closed the transaction.

Latest news about Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc. Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects	04-03	CI
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies	03-27	CI
Aligos Therapeutics, Inc. Announces the Initiation of the Phase 2a HERald Study of ALG-055009 in MASH Subjects	03-18	CI
Aligos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-12	CI
Aligos Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-12	CI
Aligos Therapeutics, Inc. Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)	12-07	CI
Aligos Therapeutics, Inc. Announces Executive Changes	11-15	CI
Aligos Therapeutics, Inc. Presents Clinical and Nonclinical Data at the AASLD Liver Meeting®? 2023	11-13	CI
Aligos Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-02	CI
Aligos Therapeutics Insider Bought Shares Worth $6,004,149, According to a Recent SEC Filing	23-10-27	MT
Aligos Therapeutics, Inc. announced that it has received $92.149997 million in funding from EcoR1 Capital, LLC, Deep Track Capital, LP, Armistice Capital LLC, Roche Venture Fund	23-10-24	CI
Aligos Therapeutics, Inc. announced that it expects to receive $92.149997 million in funding from EcoR1 Capital, LLC, Deep Track Capital, LP, Armistice Capital LLC, Roche Venture Fund and other investors	23-10-22	CI
Aligos Says Investigational New Drug Application Application Cleared By US FDA for Thyroid Hormone Receptor Beta Agonist	23-09-21	MT
Aligos Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Aligos Therapeutics Presents Data from Its Liver Disease Programs At the European Association for the Study of the Liver Congress 2023	23-06-21	CI
Sector Update: Health Care Stocks Edge Higher Premarket Monday	23-05-15	MT
Top Premarket Gainers	23-05-15	MT
Aligos Therapeutics to Collaborate with Xiamen Amoytop Biotech on Liver Disease Treatments; Aligos Shares Jump	23-05-15	MT
Aligos Therapeutics Announces Research Collaboration and Development Agreement with Xiamen Amoytop Biotech Co. Ltd. for Use of Aligos' Oligonucleotide Platform for the Treatment of Liver Diseases	23-05-12	CI
Amoytop Biotech to Co-Develop Hepatitis Treatment With US-Based Aligos	23-05-12	MT
Aligos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Earnings Flash (ALGS) ALIGOS THERAPEUTICS Posts Q4 Revenue $3.5M, vs. Street Est of $2.15M	23-03-09	MT
Aligos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-09	CI
Aligos Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-09	CI
Aligos Therapeutics Announces Portfolio Reprioritization Plans, Workforce Reduction	23-02-09	MT

Chart Aligos Therapeutics, Inc.

Duration

Period

More charts

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases. The Company discovers and develops therapeutics for metabolic dysfunction associated steatohepatitis (MASH) and viruses with high unmet medical need, such as chronic hepatitis B (CHB) and coronaviruses. Its advanced drug candidate for MASH is ALG-055009, a small molecule thyroid hormone receptor beta (THR-Ã) agonist. It is also progressing oligonucleotide projects for MASH. It is developing a portfolio of differentiated CHB drug candidates, including a small molecule Capsid Assembly Modulator that results in the production of empty viral capsids (CAM-E) and small molecule inhibitors of the Programmed Cell Death Ligand 1 (PD-1/PD-L1) interaction. Its third area of focus is to develop drug candidates with pan-coronavirus antiviral activity. Its pipeline includes ALG-055009, ALG-000184, ALG-125755, and ALG-097558.

Sector

Biotechnology & Medical Research

Calendar

2024-06-27 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.7303 USD

Average target price

7 USD

Spread / Average Target

+858.51%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ALIGOS THERAPEUTICS, INC.	+9.98%	57.04M
MODERNA, INC.	+17.96%	44.96B
LONZA GROUP AG	+48.77%	41.85B
IQVIA HOLDINGS INC.	+1.17%	42.65B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research